Stock Events

Stock Events

Galera Therapeutics 

$0.088000
21
+$0.00+0% Thursday 19:46

Statistics

Day High
0.088
Day Low
0.088
52W High
0.105
52W Low
0.016
Volume
10
Avg. Volume
318,903
Mkt Cap
6.64M
P/E Ratio
0.14
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q2 2024
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q1 2026
Next
-0.3
0.08
0.45
0.83
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
149.05MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GRTX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap193.39B
Amgen develops therapies in areas overlapping with Galera's focus on cancer supportive care, making them direct competitors in the oncology market.
Merck
MRK
Mkt Cap317.77B
Merck's extensive portfolio in oncology, including treatments that mitigate side effects of cancer therapy, places it in competition with Galera Therapeutics.
Pfizer
PFE
Mkt Cap138.44B
Pfizer has a broad range of oncology treatments and supportive care products that compete with Galera's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap117.46B
Bristol Myers Squibb's involvement in developing and marketing cancer supportive care drugs makes it a competitor to Galera Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.35B
Regeneron Pharmaceuticals, with its focus on innovative treatments in oncology, competes in the same space as Galera Therapeutics.
Gilead Sciences
GILD
Mkt Cap158.77B
Gilead Sciences' oncology and supportive care portfolio competes with Galera's focus on improving cancer treatment outcomes.
Novartis
NVS
Mkt Cap296.54B
Novartis offers a wide range of oncology treatments, including those for side effects of cancer therapy, competing with Galera Therapeutics.
Astrazeneca
AZN
Mkt Cap292.2B
AstraZeneca's commitment to developing cancer therapies and supportive care solutions places it in direct competition with Galera.
Lilly(Eli) &
LLY
Mkt Cap1.08T
Eli Lilly's portfolio in oncology and treatment of cancer side effects competes with Galera Therapeutics' focus areas.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.67B
Teva Pharmaceutical Industries, through its generic and specialty medicines, including in oncology, competes with Galera Therapeutics' specialized treatments.

About

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Show more...
CEO
Dr. J. Mel Sorensen M.D.
Employees
3
Country
United States
ISIN
US36338D1081

Listings

OTC Link
US
GRTX

0 Comments

Share your thoughts

FAQ

What is Galera Therapeutics stock price today?▼
The current price of GRTX is $0.09 USD — it has increased by +0% in the past 24 hours. Watch Galera Therapeutics stock price performance more closely on the chart.
What is Galera Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galera Therapeutics stocks are traded under the ticker GRTX.
Is Galera Therapeutics stock price growing?▼
GRTX stock has risen by +0% compared to the previous week, the month change is a -12% fall, over the last year Galera Therapeutics has showed a +203.45% increase.
What is Galera Therapeutics market cap?▼
Today Galera Therapeutics has the market capitalization of 6.64M
When is the next Galera Therapeutics earnings date?▼
Galera Therapeutics is going to release the next earnings report on August 12, 2026.
What were Galera Therapeutics earnings last quarter?▼
GRTX earnings for the last quarter are -0.01 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Galera Therapeutics revenue for the last year?▼
Galera Therapeutics revenue for the last year amounts to 0 USD.
What is Galera Therapeutics net income for the last year?▼
GRTX net income for the last year is 149.05M USD.
How many employees does Galera Therapeutics have?▼
As of July 04, 2026, the company has 3 employees.
In which sector is Galera Therapeutics located?▼
Galera Therapeutics operates in the Health & Wellness sector.
When did Galera Therapeutics complete a stock split?▼
Galera Therapeutics has not had any recent stock splits.
Where is Galera Therapeutics headquartered?▼
Galera Therapeutics is headquartered in Malvern, United States.